BioVersys
- Company typePublic
- Founded2008
- HeadquartersBasel, Switzerland
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
BioVersys firmographics
Firmographics- Name
- BioVersys
- Legal name
- BioVersys AG
- Website
- https://bioversys.com
- Company type
- Public
- Founded year
- 2008
- Operating status
- Ipo
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
BioVersys industry classification
Industry- Product category
- Infectious Disease Therapeutics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Infectious Disease Specialty Pharmaceuticals (Non-vaccine) (HLAIACAM)
- akta.pro secondary industries
- Tuberculosis & Mycobacterial Diseases (HLAKAGAH), Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG)
Keywords
Where BioVersys is headquartered
LocationHeadquarters
- HQ city
- Basel
- HQ country
- Switzerland
- HQ region
- Europe
Offices3 records
Markets served
BioVersys business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Pharmaceutical Product Revenue: BioVersys is a pre-commercial clinical-stage biopharma company generating minimal revenue. FY2025 revenue was CHF 3.3 million (likely from collaborations/grants), with an operating loss of CHF 20 million. Revenue model will shift to pharmaceutical product sales following regulatory approval of BV100, alpibectir, and pipeline assets.
- Licensing and Milestone Payments: Strategic partnerships with GSK (alpibectir), Shionogi (BV500), and others generate milestone-based non-dilutive funding and future royalty streams. Shionogi collaboration includes potential milestone payments of up to CHF 479 million plus royalties for BV500 program. GSK has taken equity stake and co-funds Phase 2 development of alpibectir.
- Non-Dilutive Funding (Grants): BioVersys secured significant non-dilutive funding from public and private organizations: IMI2 JU TRIC-TB grant (€6.92M), EDCTP grant (€2.7M), CARB-X awards (up to $8.92M for BV200, up to $15.34M for BV300), CF AMR Syndicate (up to GBP 500K), RespiriNTM EU program (up to €2M), Wellcome ADVANCE-ID network (CHF 14M), and GIBF investment (US$6M).
Go-to-market motion3 records
Distribution channels5 records
Marketing channels7 records
BioVersys product offering
Product offeringCore offering
BioVersys is a clinical-stage biopharmaceutical company developing novel small-molecule antibacterial drugs to treat serious life-threatening infections caused by multi-drug resistant bacteria. Its pipeline targets WHO and CDC priority pathogens including carbapenem-resistant Acinetobacter baumannii (CRAB), multidrug-resistant tuberculosis (MDR-TB), and non-tuberculous mycobacteria (NTM), using proprietary TRIC and Ansamycin Chemistry platforms. Lead asset BV100 (intravenous rifabutin) is in Phase 3; alpibectir is in Phase 2b with GSK.
Product overview
BioVersys is a multi-asset, clinical-stage biopharmaceutical company focused on developing novel antibacterial products for serious life-threatening infections caused by multi-drug resistant bacteria. The company's pipeline consists of clinical and preclinical assets targeting WHO and CDC priority pathogens. Lead product BV100 (Phase 3) is an intravenous rifabutin formulation for carbapenem-resistant Acinetobacter baumannii infections. Alpibectir (Phase 2b) is a tuberculosis treatment potentiator developed with GSK. The company operates two technology platforms: TRIC (Transcriptional Regulator Inhibitory Compounds) and Ansamycin Chemistry. Other programs include BV200 (anti-virulence for S. aureus), BV300 (novel ribosome inhibitor for ESKAPE pathogens), and BV500 (NTM program with Shionogi partnership).
Differentiator
Problem solved
Functional benefit
Products and services
- BV100 An innovative intravenous rifabutin formulation developed for multidrug-resistant bacterial infections, specifically targeting carbapenem-resistant Acinetobacter baumannii (CRAB) causing hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP). It has a novel mode of action and has received QIDP designation from the US FDA. Currently in Phase 3 clinical trials.
- Alpibectir (BVL-GSK098) A transcriptional regulator inhibitory compound (TRIC) that reverses resistance and potentiates the activity of ethionamide and prothionamide for treating tuberculosis, including MDR-TB and TB meningitis. It is the first drug targeting bacterial transcriptional regulators to enter human clinical trials. In Phase 2b development.
- BV200 A first-in-class anti-virulence small molecule that disarms Staphylococcus aureus bacteria (including MRSA) by abolishing toxin production, without inducing resistance. Being developed for atopic dermatitis and severe hospital infections. Currently in preclinical stage.
- BV300 A novel chemical class of small molecules inhibiting an unexploited binding site on the bacterial ribosome. Exhibits robust coverage of all ESKAPE pathogens and biothreat pathogens. Currently in preclinical development.
- BV500 A research program addressing non-tuberculous mycobacteria (NTM) infections derived from the company's proprietary Ansamycin Chemistry platform. Targets bacterial RNA polymerase (RNAP) with multiple novel molecule series that overcome resistance mechanisms. Developed under global research collaboration with Shionogi.
Quantifiable outcome
- BV100 Phase 2: 50% relative reduction in 28-day all-cause mortality compared to best available therapy for CRAB infections
- +4 more outcomes
Companies that use BioVersys
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles3 records
BioVersys technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
BioVersys partnerships and signals
Strategic signalPartnerships
Eleven partnerships are on record, tiered major, minor and core.
- Hackensack Meridian Health (HMH)majorExclusive collaboration and license agreement to develop ansamycin antimicrobial candidates targeting non-tuberculous mycobacteria (NTM) diseases. Leverages BioVersys' Ansamycin Chemistry platform and HMH's Center for Discovery and Innovation. HMH eligible for payments and royalties. Partnership addresses NTM infections affecting ~250,000 people annually, particularly cystic fibrosis and COPD patients.
- Venturelab (Venture Leaders)minorBioVersys (CEO Marc Gitzinger) has been selected for Swiss National Startup Team Venture Leaders program multiple times (2008, 2017, 2026). Program connects Swiss biotech startups with Tier 1 VCs through international roadshows (Boston 2026), helping accelerate US expansion.
- EU RespiriNTM Programme (IHI2)majorBioVersys joined the EU-funded RespiriNTM programme (Innovative Health Initiative 2) with access to up to €2 million in non-dilutive funding for BV500 NTM program development. The 8-year program explores multiple approaches for anti-mycobacterial compounds and includes consortium partners with expertise in AMR. BioVersys leads development of its candidates through preclinical and clinical studies.
- CF AMR Syndicate (LifeArc, Medicines Discovery Catapult, Cystic Fibrosis Trust)majorCF AMR Syndicate awarded up to GBP 500,000 in non-dilutive funding for BioVersys' NTM project targeting resistant non-tuberculous mycobacteria lung infections in people with cystic fibrosis. LifeArc, Medicines Discovery Catapult, and Cystic Fibrosis Trust provide complementary disease-specific support and expertise.
- GSK (GlaxoSmithKline)coreExpanded strategic collaboration to accelerate clinical development of alpibectir (BVL-GSK098) for pulmonary and meningitis TB programs. GSK took an equity stake in BioVersys and participated in Series C financing extension of CHF 12.3M (total CHF 44.9M). Under UNITE4TB project (IMI2), GSK leads Phase 2b trial of AlpE in six African countries. BioVersys and GSK co-develop alpibectir for global registration.
- Global Antibiotic Research and Development Partnership (GARDP)majorMemorandum of Understanding signed May 2020 for GARDP to support BioVersys in preparing a pediatric investigational plan (PIP) for BV100. GARDP is a non-profit organization developing new antibiotics for public health needs.
- Shionogi & Co., Ltd.coreGlobal research collaboration for BV500 program with potential milestone payments of up to CHF 479 million plus royalties. BioVersys' BV500 NTM candidates are developed under this partnership targeting non-tuberculous mycobacteria pulmonary diseases. Shionogi collaboration follows successful ansamycin platform development at BioVersys.
- WellcomemajorWellcome is funding the ADVANCE-ID Phase 2b clinical trial network with CHF 14 million to evaluate BV100 for multidrug-resistant bacterial infections in Southeast Asia. The trial will enroll patients primarily in Southeast Asia across 35 countries with an expanded cohort of 90 patients.
- Institut Pasteur de LillecoreCollaboration partner in the discovery and development of BVL-GSK098 (alpibectir) using the TRIC technology platform. Institut Pasteur de Lille contributed to the identification of the TRIC technology and continues as a key academic partner in the TRIC-TB consortium.
- University of LillecoreAcademic partner in TRIC-TB consortium contributing to the discovery of BVL-GSK098 (alpibectir). Part of the public-private partnership that developed the TRIC technology platform for TB drug discovery.
- TASK (South Africa)coreClinical research organization and consortium partner conducting the bEto-TB Phase 2a trial of alpibectir in South Africa. TASK has been a key partner in the execution of the TB clinical development program in South Africa.
Scale indicators12 records
Recent moves8 records
Expansion highlights7 records
BioVersys competitors and assessment
Company assessmentDirect peers
- Entasis Therapeutics: Entasis (acquired by Innoviva) developed sulbactam-durlobactam (XACDURO), the first FDA-approved antibiotic specifically for carbapenem-resistant Acinetobacter baumannii (CRAB) infections — a direct competitor to BioVersys' BV100 in the same CRAB hospital pneumonia indication. Most directly comparable peer.
- VenatoRx Pharmaceuticals: Clinical-stage antibacterial company developing novel therapies against MDR Gram-negative pathogens including cefepime-taniborbactam for complicated UTIs and other resistant infections. Comparable in stage, modality (small-molecule anti-infectives), and AMR focus.
- Iterum Therapeutics: Clinical-stage antibiotic developer focused on sulopenem for multi-drug resistant infections including complicated UTIs. Comparable clinical-stage profile and AMR positioning, though different therapeutic indication.
- Spexis AG (formerly Polyphor): Swiss clinical-stage biopharmaceutical company developing antibiotics for MDR Gram-negative infections (murepavadin) and rare diseases. Closest geographic and historical peer — multiple BioVersys executives previously worked at Polyphor/Spexis.
- Paratek Pharmaceuticals: Specialty biopharmaceutical company developing antibiotics including Nuzyra (omadacycline) for community-acquired pneumonia and skin infections. Comparable AMR-focused commercial/specialty antibiotics profile.
- Cidara Therapeutics: Clinical-stage biotechnology company developing novel anti-infectives, including rezafungin (approved for candidemia/invasive candidiasis) and Cloudbreak antiviral conjugates. Comparable clinical-stage anti-infective business model and modality mix.
- Nabriva Therapeutics: Biopharmaceutical company focused on commercializing antibiotics including XENLETA (lefamulin) for community-acquired bacterial pneumonia. Comparable specialty antibiotics profile targeting MDR respiratory pathogens.
Broad incumbents
- GSK: Global biopharmaceutical major with a major anti-infectives franchise. Direct partner (and equity holder) of BioVersys for alpibectir development, with deep antibiotic R&D, commercialization, and global health access infrastructure. Comparable as both partner and incumbent in same therapeutic space.
- Shionogi & Co., Ltd. Japanese multinational pharmaceutical company with a leading global antibiotics franchise (cefiderocol/Fetcroja). Partner to BioVersys for the BV500 NTM program (up to CHF 479M in potential milestones). Comparable as both strategic partner and direct incumbent in antibacterial drug development.
Others
- Melinta Therapeutics: Antibiotic-focused specialty pharma (Baxdela/delafloxacin) that emerged from Chapter 11 bankruptcy in 2020. Relevant as a cautionary benchmark for AMR commercial dynamics — illustrates the structural challenge BioVersys could face at commercialization.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key highlights6 records
Customer concentration
BioVersys social profiles
Digital presenceBioVersys financial estimates
Financial estimateRevenue estimate
Valuation estimate
BioVersys leadership team
Management profileNumber of profiles
Profiles12 records
BioVersys subsidiaries and ownership
Company hierarchySubsidiaries2 records
BioVersys funding detail
Funding detailFunding overview
Funding rounds17 records
Investors13 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BioVersys M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BioVersys
What does BioVersys do?
BioVersys is a clinical-stage biopharmaceutical company developing novel small-molecule antibacterial drugs to treat serious life-threatening infections caused by multi-drug resistant bacteria. Its pipeline targets WHO and CDC priority pathogens including carbapenem-resistant Acinetobacter baumannii (CRAB), multidrug-resistant tuberculosis (MDR-TB), and non-tuberculous mycobacteria (NTM), using proprietary TRIC and Ansamycin Chemistry platforms. Lead asset BV100 (intravenous rifabutin) is in Phase 3; alpibectir is in Phase 2b with GSK.
Is BioVersys a public or private company?
BioVersys is a public company. It is classified as public and is currently ipo.
When was BioVersys founded?
BioVersys was founded in 2008. It employs 11 to 50 people.
Where is BioVersys based?
BioVersys is headquartered in Basel, Switzerland, in the Europe region.
How does BioVersys make money?
Three revenue lines are on record. Pharmaceutical Product Revenue is the primary driver. The others are licensing and Milestone Payments and non-Dilutive Funding (Grants).
Who are BioVersys's main competitors?
Direct peers on record are Entasis Therapeutics, VenatoRx Pharmaceuticals, Iterum Therapeutics, Spexis AG (formerly Polyphor), Paratek Pharmaceuticals, Cidara Therapeutics and Nabriva Therapeutics. Broad incumbents are GSK and Shionogi & Co., Ltd.. Melinta Therapeutics is listed as an others.
Does BioVersys have an API?
No public API is recorded for BioVersys.
What industry is BioVersys in?
BioVersys's product category is Infectious Disease Therapeutics. Its primary akta.pro industry code is HLAIACAM, Infectious Disease Specialty Pharmaceuticals (Non-vaccine), with a secondary code of HLAKAGAH, Tuberculosis & Mycobacterial Diseases. Its NAICS code is 325414 and its SIC code is 2834.